Home Journals Articles Updates About
CN
image
收藏切换
Progresses and Challenges in the Treatment of Rheumatoid Arthritis
收藏切换
PDF
JIANG Ping1, 2, CHANG Cen2, 3, XU Linshuai2, SHI Yiming1, 2, HE Dongyi1, 2, 3, *
Chinese Pharmaceutical Journal | 2024, 59(3) : 200 - 209
Less
收藏切换
Chinese Pharmaceutical Journal | 2024, 59(3): 200-209
Progresses and Challenges in the Treatment of Rheumatoid Arthritis
Full
JIANG Ping1, 2, CHANG Cen2, 3, XU Linshuai2, SHI Yiming1, 2, HE Dongyi1, 2, 3, *
Affiliations
  • 1 Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China
  • 2 Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
  • 3 Arthritis Research Institute of Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China
Published: 2024-02-08 doi: 10.11669/cpj.2024.03.002
Outline
收藏切换

Rheumatoid arthritis(RA) is a chronic, systemic, and abnormal inflammatory immune response. It is characterized by the involvement of synovium and multiple organs and the destruction of joints and articular cartilage. In the past 30 years, some promising new compounds and antibodies have been developed to treat RA. The introduction of RA therapeutic drugs and the development of precision medicine have also given rise to several problems related to patients' access to new treatments, choice of the best regimen, cost-effectiveness, prognosis monitoring and efficacy monitoring, especially in terms of low drug response rate, drug resistance and adverse side effects. People attach great importance to the best combination of drugs for the treatment of RA, especially in patients with severe symptoms or early progression. New treatments and mechanisms are needed to solve these problems, and accurate guidelines for drug selection and drug recombination are established. According to the clinical trial database of the National Library of Medicine, this study summarizes the exciting new drugs, and discusses the trends and challenges in the development of RA drugs, which provides a meaningful reference for the accurate treatment and future research direction of RA.

rheumatoid arthritis  /  precision medicine  /  new therapy  /  drug development
JIANG Ping, CHANG Cen, XU Linshuai, SHI Yiming, HE Dongyi. Progresses and Challenges in the Treatment of Rheumatoid Arthritis[J]. Chinese Pharmaceutical Journal, 2024 , 59 (3) : 200 -209 . DOI: 10.11669/cpj.2024.03.002
Appendix
Less
Year 2024 volume 59 Issue 3
PDF
230
109
Cite this Article
BibTeX
Article Info
doi: 10.11669/cpj.2024.03.002
  • Receive Date：2023-09-12
  • Online Date：2025-11-13
  • Published：2024-02-08
Article Data
Affiliations
History
  • Received：2023-09-12
Funding
Affiliations
    1 Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200052, China
    2 Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    3 Arthritis Research Institute of Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China
References
Share
https://castjournals.cast.org.cn/joweb/zgyxzz/EN/10.11669/cpj.2024.03.002
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House